Today, the biomedical industry is a key track in the global innovation race.From September 12 to 14, the symposium themed "Innovation, Integration, and Development" took place at the Shanghai Nanjiao Hotel. Co-sponsored by the Shanghai Biomedical Science and Technology Industry Promotion Center along with relevant government departments from Fengxian District, this conference aimed to foster international exchanges and dialogue within the biomedicine sector, share cutting-edge scientific advancements, accelerate innovation transformation, explore multilateral industrial cooperation opportunities, and promote high-quality development in the biomedical industry.
What does the future hold for biopharmaceutical development? How do advanced biological therapies achieve breakthroughs? How can we effectively configure elements of the biomedical industry chain? Focusing on "Innovation, Integration, and Development," over 200 experts in biomedicine—including renowned pharmaceutical entrepreneurs and executives from innovative enterprises—gathered from more than 20 countries to address global health challenges as well as issues related to innovative drug research and development investment. They shared pioneering scientific research findings while seeking solutions to complex problems that inject new vitality into high-quality growth within the biomedical field. Sixteen parallel sessions covered topics such as innovative drug discovery; new antibody therapies; vaccines; biotherapeutics; alongside fresh strategies for anti-tumor diagnostics.
Professor Wenqiang Yu, Chief Scientist at Epiprobe Biotech was invited to participate in keynote speeches, high-level dialogues, roundtable forums among other sessions where he introduced UCOM's application in cancer detection. He emphasized DNA methylation's significance as an early cancer marker while demonstrating how methylation patterns evolve during cancer progression. As a novel biomarker characterized by an all-or-nothing profile capable of detecting malignant tumors even prior to pathological changes occurring—UCOM has patents filed both domestically in China and internationally showcasing its potential applications globally. Utilizing Me-qPCR allows for assessing UCOM’s methylation status without requiring sulfite***.
Clinical validations have indicated that UCOM exhibits high specificity and sensitivity across various cancers including cervical carcinoma; urothelial carcinoma; lung cancer; endometrial carcinoma among others. Its applications extend beyond mere early detection of malignancies encompassing risk assessment for cancers; monitoring responses during treatments along with predicting recurrences—for instance—in urothelial cancer detection where UCOM demonstrated superior diagnostic sensitivity compared with conventional urine cytology methods enabling identification of early-stage cancers via random urine samples collected conveniently. Furthermore,UCOM serves as an adjunct tool aiding HPV-positive women undergoing cervical screening thereby minimizing unnecessary referrals whilst enhancing cervical cancer detection capabilities.
Professor Yu Wenqiang stated that timely screening coupled with accurate diagnoses significantly enhances patient survival rates given current established methodologies are often unsuitable due their costs complexity or dependence upon specialized medical equipment rendering them impractical for routine public screenings.Under these circumstances,the whole-cancer marker known as UCOM presents itself offering transformative prospects regarding early detections,risk assessments,and therapeutic response evaluations throughout comprehensive management processes associated with oncological care.The series comprising TAGMe® products based around total-cancer markers exhibit precision accuracy stability making them viable options suitable even amongst general populations facilitating effective daily health examinations monitoring routines.
This conference will delve deeply into discussions surrounding cutting-edge technologies achievement transformations regulatory policies offshore strategies investment approaches ultimately contributing positively towards fostering deeper integrations between biomedical innovation chains industrial frameworks policy structures.Adel K.El-Naggar,a professor affiliated with University Texas MD Anderson Cancer Center remarked this gathering provides invaluable platforms bridging scientific inquiry alongside industrial progressions pertinent within biotechnology sectors aligning leading inventions technological achievements against expansive global market demands thus propelling further advancement across entire bioscience domains.
Post time: Oct-12-2024